肿瘤转录组学市场－全球产业规模、份额、趋势、机会和预测，依肿瘤类型、技术、产品、应用、最终用户和地区划分，竞争格局，2020-2030年预测

2024年全球肿瘤转录组学市场规模为60.2亿美元，预计2030年将以6.34%的复合年增长率成长至87.1亿美元。肿瘤转录组学是对癌细胞内核糖核酸转录物进行全面分析，从而深入了解基因表现模式、疾病分类和进展。该市场的成长主要得益于全球各类癌症发生率的不断上升以及基因组定序技术的持续进步。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：客户之声

第五章：全球肿瘤转录组学市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依肿瘤类型（乳癌、肺癌、大肠癌、摄护腺癌、黑色素瘤、其他）
  • 依技术分类（微阵列、即时定量PCR、聚合酶炼式反应（Q-PCR）、其他）
  • 依产品分类（耗材、仪器、软体及服务）
  • 按应用领域（诊断和疾病分析、药物发现、其他）
  • 按最终用户分类（生物技术和製药公司、研究和学术机构、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美肿瘤转录组学市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲肿瘤转录组学市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区肿瘤转录组学市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲肿瘤转录组学市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲肿瘤转录组学市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球肿瘤转录组学市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Thermo Fischer Scientific, Inc.
• Caris Life Sciences.
• Illumina, Inc.
• NanoString Technologies, Inc.
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Standard BioTools Inc.
• Pacific Biosciences of California, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Tumor Transcriptomics Market, valued at USD 6.02 Billion in 2024, is projected to experience a CAGR of 6.34% to reach USD 8.71 Billion by 2030. Tumor transcriptomics involves the comprehensive analysis of ribonucleic acid transcripts within cancer cells, providing essential insights into gene expression patterns, disease classification, and progression. This market's expansion is primarily supported by the increasing global prevalence of various cancer types and continuous advancements in genomic sequencing technologies.

Key Market Drivers

The escalating global incidence of cancer serves as a primary catalyst for the expansion of the tumor transcriptomics market. As cancer rates continue to rise across diverse populations, there is a sustained demand for sophisticated diagnostic and prognostic tools capable of unraveling complex molecular signatures of various tumor types. Tumor transcriptomics offers unparalleled insights into gene expression patterns and disease progression, crucial for effective clinical management and treatment stratification. According to the International Agency for Research on Cancer, in February 2024, "Global cancer burden growing, amidst mounting need for services" article, in 2022 there were an estimated 20 million new cancer cases worldwide, highlighting the extensive patient population requiring advanced molecular profiling. This pervasive disease burden necessitates continuous innovation in transcriptomic analysis to provide actionable information for clinicians.

Key Market Challenges

The scarcity of professionals possessing specialized expertise in both molecular biology and the bioinformatics required for complex analysis represents a significant impediment to the Global Tumor Transcriptomics Market's expansion. These specialists are critical for interpreting the vast and intricate transcriptomic datasets, which are fundamental for precise disease classification, understanding progression, and guiding therapeutic strategies. Without sufficient qualified personnel, the advanced genomic sequencing technologies, despite continuous advancements, cannot be fully leveraged.

Key Market Trends

The emergence of spatial tumor transcriptomics for tissue analysis is significantly influencing the market by enabling researchers to precisely map gene expression within the architectural context of a tumor, providing insights into cellular interactions and disease microenvironments that bulk sequencing cannot. This technology is becoming crucial for understanding tumor heterogeneity and identifying novel biomarkers for targeted therapies. For example, Vizgen, a company at the forefront of this technology, announced the first global shipments of its MERSCOPE Ultra Platform in September 2024, delivering enhanced capabilities to leading research institutions worldwide to accelerate discoveries in spatial genomics. This advancement, which triples the imaging area of its predecessor to 3.0 cm2 on a single slide and offers faster imaging speeds, underscores the growing demand for high-resolution spatial multiomic analysis systems to propel foundational and clinical research.

Key Market Players

• Thermo Fischer Scientific, Inc.
• Caris Life Sciences.
• Illumina, Inc.
• NanoString Technologies, Inc.
• 10x Genomics, Inc.
• Agilent Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• F. Hoffmann-La Roche AG
• Standard BioTools Inc.
• Pacific Biosciences of California, Inc.

Report Scope:

In this report, the Global Tumor Transcriptomics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Tumor Transcriptomics Market, By Tumor Type:

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer
• Melanoma
• Others

Tumor Transcriptomics Market, By Technology:

• Microarray
• Real-Time Quantitative
• Polymerase Chain Reaction (Q-PCR)
• Others

Tumor Transcriptomics Market, By Product:

• Consumables
• Instrument
• Software & Services

Tumor Transcriptomics Market, By Application:

• Diagnostics and Disease Profiling
• Drug Discovery
• Others

Tumor Transcriptomics Market, By End User:

• Biotechnology & Pharmaceutical Companies
• Research & Academic Institutions
• Others

Tumor Transcriptomics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Tumor Transcriptomics Market.

Available Customizations:

Global Tumor Transcriptomics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Tumor Transcriptomics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others)
  • 5.2.2. By Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Others)
  • 5.2.3. By Product (Consumables, Instrument, Software & Services)
  • 5.2.4. By Application (Diagnostics and Disease Profiling, Drug Discovery, Others)
  • 5.2.5. By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Tumor Transcriptomics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Tumor Type
  • 6.2.2. By Technology
  • 6.2.3. By Product
  • 6.2.4. By Application
  • 6.2.5. By End User
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Tumor Transcriptomics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Tumor Type
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Product
      • 6.3.1.2.4. By Application
      • 6.3.1.2.5. By End User
  • 6.3.2. Canada Tumor Transcriptomics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Tumor Type
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Product
      • 6.3.2.2.4. By Application
      • 6.3.2.2.5. By End User
  • 6.3.3. Mexico Tumor Transcriptomics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Tumor Type
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Product
      • 6.3.3.2.4. By Application
      • 6.3.3.2.5. By End User

7. Europe Tumor Transcriptomics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Tumor Type
  • 7.2.2. By Technology
  • 7.2.3. By Product
  • 7.2.4. By Application
  • 7.2.5. By End User
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Tumor Transcriptomics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Tumor Type
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Product
      • 7.3.1.2.4. By Application
      • 7.3.1.2.5. By End User
  • 7.3.2. France Tumor Transcriptomics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Tumor Type
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Product
      • 7.3.2.2.4. By Application
      • 7.3.2.2.5. By End User
  • 7.3.3. United Kingdom Tumor Transcriptomics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Tumor Type
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Product
      • 7.3.3.2.4. By Application
      • 7.3.3.2.5. By End User
  • 7.3.4. Italy Tumor Transcriptomics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Tumor Type
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Product
      • 7.3.4.2.4. By Application
      • 7.3.4.2.5. By End User
  • 7.3.5. Spain Tumor Transcriptomics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Tumor Type
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Product
      • 7.3.5.2.4. By Application
      • 7.3.5.2.5. By End User

8. Asia Pacific Tumor Transcriptomics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Tumor Type
  • 8.2.2. By Technology
  • 8.2.3. By Product
  • 8.2.4. By Application
  • 8.2.5. By End User
  • 8.2.6. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Tumor Transcriptomics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Tumor Type
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Product
      • 8.3.1.2.4. By Application
      • 8.3.1.2.5. By End User
  • 8.3.2. India Tumor Transcriptomics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Tumor Type
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Product
      • 8.3.2.2.4. By Application
      • 8.3.2.2.5. By End User
  • 8.3.3. Japan Tumor Transcriptomics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Tumor Type
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Product
      • 8.3.3.2.4. By Application
      • 8.3.3.2.5. By End User
  • 8.3.4. South Korea Tumor Transcriptomics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Tumor Type
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Product
      • 8.3.4.2.4. By Application
      • 8.3.4.2.5. By End User
  • 8.3.5. Australia Tumor Transcriptomics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Tumor Type
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Product
      • 8.3.5.2.4. By Application
      • 8.3.5.2.5. By End User

9. Middle East & Africa Tumor Transcriptomics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Tumor Type
  • 9.2.2. By Technology
  • 9.2.3. By Product
  • 9.2.4. By Application
  • 9.2.5. By End User
  • 9.2.6. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Tumor Transcriptomics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Tumor Type
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Product
      • 9.3.1.2.4. By Application
      • 9.3.1.2.5. By End User
  • 9.3.2. UAE Tumor Transcriptomics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Tumor Type
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Product
      • 9.3.2.2.4. By Application
      • 9.3.2.2.5. By End User
  • 9.3.3. South Africa Tumor Transcriptomics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Tumor Type
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Product
      • 9.3.3.2.4. By Application
      • 9.3.3.2.5. By End User

10. South America Tumor Transcriptomics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Tumor Type
  • 10.2.2. By Technology
  • 10.2.3. By Product
  • 10.2.4. By Application
  • 10.2.5. By End User
  • 10.2.6. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Tumor Transcriptomics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Tumor Type
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Product
      • 10.3.1.2.4. By Application
      • 10.3.1.2.5. By End User
  • 10.3.2. Colombia Tumor Transcriptomics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Tumor Type
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Product
      • 10.3.2.2.4. By Application
      • 10.3.2.2.5. By End User
  • 10.3.3. Argentina Tumor Transcriptomics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Tumor Type
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Product
      • 10.3.3.2.4. By Application
      • 10.3.3.2.5. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Tumor Transcriptomics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fischer Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Caris Life Sciences.
• 15.3. Illumina, Inc.
• 15.4. NanoString Technologies, Inc.
• 15.5. 10x Genomics, Inc.
• 15.6. Agilent Technologies, Inc.
• 15.7. Bio-Rad Laboratories, Inc.
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Standard BioTools Inc.
• 15.10. Pacific Biosciences of California, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer